ITM0166
ITM0166
- Catalog: ITM0166
- Gene/Protein: CRK
- Product Description: Immunotag™ Crk II Monoclonal Antibody
504.0000
Price in reward points: 504
Your shopping cart is empty!
Antibody Specification | |
Datasheet | |
Target Protein | Crk II |
Clonality | Monoclonal |
Storage/Stability | -20°C/1 year |
Application | WB,IHC-p,IF,FCM,ELISA |
Recommended Dilution | Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/200 - 1/1000. Immunofluorescence: 1/200 - 1/1000. Flow cytometry: 1/200 - 1/400. ELISA: 1/10000. Not yet tested in other applications. |
Concentration | 1 mg/ml |
Reactive Species | Human |
Host Species | Mouse |
Immunogen | Purified recombinant fragment of human Crk II expressed in E. Coli. |
Specificity | Crk II Monoclonal Antibody detects endogenous levels of Crk II protein. |
Purification | Affinity purification |
Form | Ascitic fluid containing 0.03% sodium azide. |
Gene Name | CRK |
Accession No. | P46108 Q64010 |
Alternate Names | CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38 |
Description | CRK proto-oncogene, adaptor protein(CRK) Homo sapiens This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008], |
Cell Pathway/ Category | MAPK_ERK_Growth,MAPK_G_Protein,ErbB_HER,Chemokine,Focal adhesion,Fc gamma R-mediated phagocytosis,Neurotrophin,Regulates Actin and Cytoskeleton,Insulin_Receptor,Pathways in cancer,Renal cell carcinoma,Chronic myeloid leukemia, |
Protein Expression | Embryonic lung,Epithelium,Eye,Lung,Placenta, |
Subcellular Localization | nucleus,cytoplasm,cytosol,plasma membrane,actin cytoskeleton,extracellular exosome, |
Protein Function | domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the down-regulation of the Crk signaling pathway.,PTM:Phosphorylation of Crk-II (40 kDa) gives rise to a 42 kDa form.,similarity:Contains 1 SH2 domain.,similarity:Contains 1 SH3 domain.,similarity:Contains 2 SH3 domains.,subcellular location:Translocated to the plasma membrane upon cell adhesion.,subunit:Interacts with ABL1, C3G, SOS, MAP4K1, MAPK8 and DOCK3 via its first SH3 domain. Interacts with BCAR1, CBL, CBLB, PXN, IRS4 and GAB1 via its SH2 domain upon stimulus-induced tyrosine phosphorylation. Interacts with several tyrosine-phosphorylated growth factor receptors such as EGFR, PDGFR and INSR via its SH2 domain (By similarity). Interacts with DOCK1 and DOCK4. Interacts with SHB., |
Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |